Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

14P - Classification of molecular subtypes of breast cancer in whole-slide histopathological images using a novel deep learning algorithm

Date

02 Dec 2023

Session

Poster Display

Presenters

Hyung Suk Kim

Citation

Annals of Oncology (2023) 34 (suppl_4): S1467-S1479. 10.1016/annonc/annonc1374

Authors

H.S. Kim1, K. Min2, J.S. Kim3

Author affiliations

  • 1 Breast Surgical Oncologist, Hanyang University College of Medicine, 04763 - Seoul/KR
  • 2 Pathology, Uijeongbu Eulji Medical Center, Gyeonggi-do/KR
  • 3 Institute For Software Convergence, Hanyang University - Seoul Campus, 04763 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 14P

Background

Classification of molecular subtypes of breast cancer is widely used in clinical decision-making, leading to different treatment responses and clinical outcomes. We classified molecular subtypes using a novel deep learning algorithm in whole-slide histopathological images (WSIs) with invasive ductal carcinoma of the breast.

Methods

We obtained 1,094 breast cancer cases with available hematoxylin and eosin-stained WSIs from the TCGA database. We applied a new deep learning algorithm for artificial neural networks (ANNs) that is completely different from the back-propagation method developed in previous studies.

Results

Our model based on the ANN algorithm had an accuracy of 67.8% for all datasets (training and testing), and the area under the receiver operating characteristic curve was 0.819 when classifying molecular subtypes of breast cancer. In approximately 30% of cases, the molecular subtype did not reflect the unique histological subtype, which lowered the accuracy. The set revealed relatively high sensitivity (70.5%) and specificity (84.4%).

Conclusions

Our approach involving this ANN model has favorable diagnostic performance for molecular classification of breast cancer based on WSIs and could provide reliable results for planning treatment strategies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.